Open AccessCombined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates
Author(s) -
Dominic C. Borie,
Michael J. Larson,
Mona G. Flores,
Andrew Campbell,
Géraldine Rousvoal,
Sally Zhang,
Julian P T Higgins,
Douglas J. Ball,
Elizabeth M. Kudlacz,
William H. Brissette,
Eileen A. Elliott,
Bruce A. Reitz,
Paul S. Changelian
Publication year - 2005
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000184634.25042.ea
Subject(s) - medicine , regimen , calcineurin , immunosuppression , gastroenterology , mycophenolate , tacrolimus , renal function , kidney , urology , transplantation , immunology , pharmacology
Immunosuppression via Janus kinase (JAK) 3 inhibition affords significant prolongation of allograft survival. We investigated the effects of an immunosuppressive regimen combining the JAK3 inhibitor CP-690,550 with mycophenolate mofetil (MMF) in nonhuman primates (NHPs).